Description: ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Category: Health
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock US | 71.90 | 0.00 | 71.90 |
| Stock non-US | 28.05 | 0.00 | 28.05 |
| Cash | 0.07 | 0.03 | 0.04 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 100.00 | 99.57 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 71.93 | 92.60 |
| Europe Developed | 17.27 | 4.28 |
| United Kingdom | 6.67 | 1.65 |
| Asia Emerging | 4.13 | 0.82 |
| Japan | 0.00 | 0.54 |
| Australasia | 0.00 | 0.11 |
| Africa/Middle East | 0.00 | 0.02 |